The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality.
No antiviral treatment for coronavirus infection has been proven to be effective. In a historical control study, the combination of lopinavir and ritonavir among SARS-CoV patients was associated with substantial clinical benefit (fewer adverse clinical outcomes).
Huang, C. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext
克力芝是一個復方製劑，包括「洛匹那韋」（lopinavir）和「利托那韋」（ritonavir）兩種成分。由於主要成分洛匹那韋（lopinavir），屬於蛋白酶抑製劑，主要通過和病毒蛋白酶結合抑制蛋白酶功能……而冠狀病毒的複製也需要病毒蛋白酶的作用。
Some viruses are highly contagious (like measles), while other viruses are less so. It’s not clear yet how easily 2019-nCoV spreads from person-to-person. It’s important to know this in order to better assess the risk posed by this virus. While CDC considers this is a very serious public health threat, based on current information, the immediate health risk from 2019-nCoV to the general American public is considered low at this time. Nevertheless, CDC is taking proactive preparedness precautions.
https://www.cdc.gov/coronavirus/2019-ncov/summary.html
SARS-CoV is thought to be transmitted most readily by respiratory droplets produced when an infected person coughs or sneezes. Droplet spread can happen when droplets from the cough or sneeze of an infected person are propelled a short distance (generally up to 3 feet) through the air and deposited on the mucous membranes of the mouth, nose, or eyes of persons who are nearby. The virus also can spread when a person touches a surface or object contaminated with infectious droplets and then touches his or her mouth, nose, or eye(s). In addition, it is possible that SARS-CoV might be spread more broadly through the air (airborne spread) or by other ways that are not now known.
https://www.cdc.gov/sars/about/faq.html
沒有留言:
發佈留言